Angiotensin ii receptor blockers vs ace inhibitors
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Comparative Analysis of Angiotensin II Receptor Blockers vs. ACE Inhibitors
Introduction to Angiotensin II Receptor Blockers and ACE Inhibitors
Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACE inhibitors) are two classes of medications commonly used to manage hypertension and other cardiovascular conditions. Both classes target the renin-angiotensin system but through different mechanisms. This article synthesizes current research comparing the efficacy and safety of ARBs and ACE inhibitors.
Cardiovascular Outcomes in High-Risk Patients
Cardiovascular Mortality and Morbidity
A network meta-analysis involving 27 randomized controlled trials with 125,330 patients found no significant differences between ARBs and ACE inhibitors in preventing cardiovascular death, myocardial infarction (MI), and stroke in high cardiovascular risk patients without heart failure. Similarly, a secondary analysis of the ACCORD-BP and SPRINT trials indicated that new users of ARB-based regimens experienced similar rates of cardiovascular events compared to those on ACE inhibitor-based regimens, with ARBs showing a lower overall death rate.
Heart Failure and Acute Myocardial Infarction
In patients with chronic heart failure and high-risk acute myocardial infarction, ARBs and ACE inhibitors have shown comparable efficacy in reducing afterload and increasing cardiac output. However, ACE inhibitors are generally preferred due to their additional benefits in reducing inflammatory cytokines. The American College of Cardiology and the Heart Failure Society of America recommend ACE inhibitors as first-line therapy, with ARBs as an alternative for those intolerant to ACE inhibitors.
Hypertension and Insulin Sensitivity
Blood Pressure Control
A systematic review comparing ACE inhibitors and ARBs in adults with essential hypertension found that both classes have similar long-term effects on blood pressure. However, ACE inhibitors are more frequently associated with adverse effects like cough.
Insulin Sensitivity
A meta-analysis of randomized controlled trials indicated that ACE inhibitors might be more effective than ARBs in improving insulin sensitivity, particularly in long-term interventions and in hypertensive patients with diabetes mellitus. This suggests a potential advantage of ACE inhibitors in managing metabolic aspects of hypertension.
Kidney and Cardiovascular Outcomes in CKD Patients
A Bayesian network meta-analysis of 119 randomized controlled trials involving patients with chronic kidney disease (CKD) showed that both ACE inhibitors and ARBs significantly reduce the risk of kidney failure and major cardiovascular events compared to placebo. However, ACE inhibitors were associated with a greater reduction in all-cause mortality and possibly superior outcomes in kidney failure and cardiovascular death compared to ARBs.
Diabetes Mellitus and New-Onset Type 2 Diabetes
Cardiovascular Events in Diabetic Patients
A meta-analysis focusing on patients with diabetes mellitus found that ACE inhibitors significantly reduced all-cause mortality, cardiovascular deaths, and major cardiovascular events, whereas ARBs did not show significant benefits in these outcomes, except for heart failure. This suggests that ACE inhibitors may be more beneficial for diabetic patients in reducing cardiovascular risks.
Prevention of New-Onset Type 2 Diabetes
Both ACE inhibitors and ARBs have been shown to decrease the incidence of new-onset type 2 diabetes, likely due to their effects on reducing hepatic glucose production and improving insulin sensitivity. This benefit is consistent across various indications, including hypertension, coronary artery disease, and heart failure.
Conclusion
In summary, while both ARBs and ACE inhibitors are effective in managing hypertension and reducing cardiovascular risks, ACE inhibitors may offer additional benefits in terms of reducing all-cause mortality, improving insulin sensitivity, and preventing new-onset type 2 diabetes. However, ARBs are a valuable alternative, particularly for patients who experience adverse effects from ACE inhibitors. The choice between these two classes should be individualized based on patient-specific factors and comorbidities.
Sources and full results
Most relevant research papers on this topic